Regulardoc,
10 years ago I would agree with you. Glatopa spent most of 2016 as the class 3 drug, too no avail.
The majors (Teva included) funnel money through controlled charities and they'll make sure you don't pay one penny more than any other drug. This is now under some state inspections right now but nothing has come out of it so far.
While Teva wants too make as money as possible, they have already shown their cards in that they told investors they are going to increase their Copaxone marketing expenses to retain share. Knowing Teva, this won't be in advertising but rather they'll fortify their Neuro network.
If this method fails, they'll be the cheapest drug on the market.
Market Data 
Markets 
AI
